High dose methylprednisolone therapy in nephrotic syndrome

被引:11
作者
Mocan H. [1 ,2 ]
Erduran E. [1 ]
Karagüzel G. [1 ]
机构
[1] Department of Pediatrics, Karadeniz (Black Sea) Tech. Univ., Faculty of Medicine, Trabzon
[2] Department of Pediatrics, American Hospital, Nisantapi, Istanbul
关键词
Methylprednisolone; Nephrotic syndrome;
D O I
10.1007/BF02761198
中图分类号
学科分类号
摘要
This study was done to determine the efficacy of oral high dose methylprednisolone (HDMP) therapy in the treatment of childhood nephrotic syndrome (NS). Fifteen patients were enrolled in the study. Patients were arbitrarily divided into two groups. Group I received prednisolone (daily 60 mg/m2 for 4 weeks, 45, 30, 20, 10, 5 mg/m2 on alternate days for 4 weeks) and group II received HDMP (30 mg/kg/d for 3 days, 20 mg/kg/d for 4 days, 10 mg/kg/for a week, before 9 am, orally). The patients were followed-up for a duration of 38.0 ± 5.5 months (range 24-68 months) in group I and 42.1 ± 5.5 months (range 16-72 months) in group II. No significant difference was obtained in the duration of remission between both groups (p > 0.05), while HDMP induced early remission than prednisolone (p < 0.05). The mean relapse rate was 0.8/year in group I and 0.8/year in group II (p > 0.05). Although, the number of the patients were limited in the study it can be recommended that patients with NS can be treated with oral HDMP therapy as an alternative to standard oral prednisolone therapy.
引用
收藏
页码:171 / 174
页数:3
相关论文
共 8 条
[1]  
Churg J., Habib R., White R.H.R., Pathology of the nephrotic syndrome in children. A report of the International Study of Kidney Disease in Children, Lancet, 1, pp. 1299-1302, (1970)
[2]  
White R.H.R., Glaskow E.F., Mills R.J., Clinicopathological study of nephrotic syndrome in childhood, Lancet, 1, pp. 1353-1359, (1970)
[3]  
Barnett H.C., Mc. Namara H., Mc Crory W., Et al., Effect of ACTH and cortisone on the nephrotic syndrome, Am J Dis Child, 80, pp. 519-520, (1950)
[4]  
Schnaper H.W., The immunesystem in minimal change nephrotic syndrome, Pediatr Nephrol, 3, pp. 101-110, (1989)
[5]  
Shalhoub R.J., Pathogenesis of lipoid nephrosis - A disorder of T cell function, Lancet, 2, pp. 556-560, (1974)
[6]  
Barnett H.L., Schoeneman M., Bernstein J., Et al., Minimal change nephrotic syndrome, Pediatric Kidney Disease, pp. 695-711, (1978)
[7]  
Young C.K., Wong K.L., Ng W.L., Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome, Aust N Z J Med, 13, pp. 349-351, (1983)
[8]  
Baylis E.M., Williams I.A., English J., Et al., High dose intravenous methylprednisolone pulse therapy in patients with rheumatoid disease, Eur J Clin Pharmacol, 21, pp. 385-388, (1982)